sequor-0.1: data/devel.conll

the DT B-NP
Friendly NNP I-NP
Skies NNPS I-NP
-- : O
free JJ B-NP
first-class JJ I-NP
travel NN I-NP
, , O
and CC O
$ $ B-NP
20,000 CD I-NP
a DT B-NP
year NN I-NP
for IN B-PP
life NN B-NP
as IN B-ADVP
well RB I-ADVP
. . O

Conceivably RB B-ADVP
, , O
in IN B-PP
a DT B-NP
scaled-back JJ I-NP
buy-out NN I-NP
, , O
they PRP B-NP
could MD B-VP
be VB I-VP
bumped VBN I-VP
back RB B-ADVP
to TO B-PP
coach NN B-NP
seats NNS I-NP
for IN B-PP
life NN B-NP
. . O

Thomas NNP B-NP
H. NNP I-NP
Johnson NNP I-NP
, , O
president NN B-NP
of IN B-PP
the DT B-NP
Coatedboard NNP I-NP
division NN I-NP
of IN B-PP
Mead NNP B-NP
Corp. NNP I-NP
, , O
was VBD B-VP
named VBN I-VP
president NN B-NP
of IN B-PP
Manville NNP B-NP
Forest NNP I-NP
Products NNP I-NP
Corp. NNP I-NP
, , O
a DT B-NP
Manville NNP I-NP
unit NN I-NP
, , O
and CC O
senior JJ B-NP
vice NN I-NP
president NN I-NP
of IN B-PP
Manville NNP B-NP
Corp NNP I-NP
. . O

Mr. NNP B-NP
Johnson NNP I-NP
succeeds VBZ B-VP
Harry NNP B-NP
W. NNP I-NP
Sherman NNP I-NP
, , O
who WP B-NP
resigned VBD B-VP
to TO B-VP
pursue VB I-VP
other JJ B-NP
interests NNS I-NP
, , O
in IN B-PP
both DT B-NP
positions NNS I-NP
. . O

Manville NNP B-NP
is VBZ B-VP
a DT B-NP
building NN I-NP
and CC I-NP
forest NN I-NP
products NNS I-NP
concern VBP I-NP
. . O

US PRP B-NP
Facilities NNP I-NP
Corp. NNP I-NP
said VBD B-VP
Robert NNP B-NP
J. NNP I-NP
Percival NNP I-NP
agreed VBD B-VP
to TO I-VP
step VB I-VP
down RB B-ADVP
as IN B-PP
vice NN B-NP
chairman NN I-NP
of IN B-PP
the DT B-NP
insurance NN I-NP
holding VBG I-NP
company NN I-NP
. . O

`` `` O
There EX B-NP
was VBD B-VP
a DT B-NP
difference NN I-NP
of IN B-PP
opinion NN B-NP
as IN B-PP
to TO B-PP
the DT B-NP
future NN I-NP
direction NN I-NP
of IN B-PP
the DT B-NP
company NN I-NP
, , O
'' '' O
a DT B-NP
spokeswoman NN I-NP
said VBD B-VP
. . O

Mr. NNP B-NP
Percival NNP I-NP
declined VBD B-VP
to TO I-VP
comment VB I-VP
. . O

In IN B-PP
a DT B-NP
statement NN I-NP
, , O
US PRP B-NP
Facilities NNPS I-NP
said VBD B-VP
Mr. NNP B-NP
Percival NNP I-NP
's POS B-NP
employment NN I-NP
contract NN I-NP
calls VBZ B-VP
for IN B-SBAR
him PRP B-NP
to TO B-VP
act VB I-VP
as IN B-PP
a DT B-NP
consultant NN I-NP
to TO B-PP
the DT B-NP
company NN I-NP
for IN B-PP
two CD B-NP
years NNS I-NP
. . O

He PRP B-NP
will MD B-VP
also RB I-VP
remain VB I-VP
a DT B-NP
director NN I-NP
, , O
US PRP B-NP
Facilities NNPS I-NP
said VBD B-VP
, , O
but CC O
wo MD B-VP
n't RB I-VP
serve VB I-VP
on IN B-PP
any DT B-NP
board NN I-NP
committees NNS I-NP
. . O

Mr. NNP B-NP
Percival NNP I-NP
will MD B-VP
be VB I-VP
succeeded VBN I-VP
on IN B-PP
an DT B-NP
interim JJ I-NP
basis NN I-NP
by IN B-PP
George NNP B-NP
Kadonada NNP I-NP
, , O
US PRP B-NP
Facilities NNPS I-NP
chairman NN I-NP
and CC I-NP
president NN I-NP
. . O

In IN B-PP
the DT B-NP
same JJ I-NP
statement NN I-NP
, , O
US PRP B-NP
Facilities NNPS I-NP
also RB B-ADVP
said VBD B-VP
it PRP B-NP
had VBD B-VP
bought VBN I-VP
back RB B-ADVP
112,000 CD B-NP
of IN B-PP
its PRP$ B-NP
common JJ I-NP
shares NNS I-NP
in IN B-PP
a DT B-NP
private JJ I-NP
transaction NN I-NP
. . O

Terms NNS B-NP
were VBD B-VP
n't RB I-VP
disclosed VBN I-VP
. . O

The DT B-NP
buy-back NN I-NP
represents VBZ B-VP
about IN B-NP
3 CD I-NP
% NN I-NP
of IN B-PP
the DT B-NP
company NN I-NP
's POS B-NP
shares NNS I-NP
, , O
based VBN B-VP
on IN B-PP
the DT B-NP
3.7 CD I-NP
million CD I-NP
shares NNS I-NP
outstanding JJ B-ADJP
as IN B-PP
of IN B-PP
Sept. NNP B-NP
30 CD I-NP
. . O

In IN B-PP
national JJ B-NP
over-the-counter JJ I-NP
trading NN I-NP
yesterday NN B-NP
, , O
US PRP B-NP
Facilities NNPS I-NP
closed VBD B-VP
at IN B-PP
$ $ B-NP
3.625 CD I-NP
, , O
unchanged JJ B-ADJP
. . O

Three CD B-NP
leading VBG I-NP
drug NN I-NP
companies NNS I-NP
reported VBD B-VP
robust JJ B-NP
third-quarter JJ I-NP
earnings NNS I-NP
, , O
bolstered VBN B-VP
by IN B-PP
strong JJ B-NP
sales NNS I-NP
of IN B-PP
newer JJR B-NP
, , I-NP
big-selling JJ I-NP
prescriptions NNS I-NP
drugs NNS I-NP
that WDT B-NP
provide VBP B-VP
hefty JJ B-NP
profit NN I-NP
margins NNS I-NP
. . O

Merck NNP B-NP
& CC I-NP
Co. NNP I-NP
reported VBD B-VP
a DT B-NP
25 CD I-NP
% NN I-NP
increase NN I-NP
in IN B-PP
earnings NNS B-NP
; : O
Warner-Lambert NNP B-NP
Co. NNP I-NP
's POS B-NP
profit NN I-NP
rose VBD B-VP
22 CD B-NP
% NN I-NP
and CC O
Eli NNP B-NP
Lilly NNP I-NP
& CC I-NP
Co. NNP I-NP
's POS B-NP
net JJ I-NP
income NN I-NP
rose VBD B-VP
24 CD B-NP
% NN I-NP
. . O

The DT B-NP
results NNS I-NP
were VBD B-VP
in IN B-PP
line NN B-NP
with IN B-PP
analysts NNS B-NP
' POS B-NP
expectations NNS I-NP
. . O

Merck NNP B-NP
& CC I-NP
Co NNP I-NP
. . O

Merck NNP B-NP
, , O
Rahway NNP B-NP
, , O
N.J. NNP B-NP
, , O
continued VBD B-VP
to TO I-VP
lead VB I-VP
the DT B-NP
industry NN I-NP
with IN B-PP
a DT B-NP
strong JJ I-NP
sales NNS I-NP
performance NN I-NP
in IN B-PP
the DT B-NP
human NN I-NP
and CC I-NP
animal NN I-NP
health-products NNS I-NP
segment VBP I-NP
. . O

A DT B-NP
stronger JJR I-NP
U.S. NNP I-NP
dollar NN I-NP
reduced VBD B-VP
third-quarter JJ B-NP
and CC I-NP
first-nine-month JJ I-NP
sales NNS I-NP
growth NN I-NP
2 CD B-NP
% NN I-NP
and CC I-NP
3 CD I-NP
% NN I-NP
, , O
respectively RB B-ADVP
. . O

International JJ B-NP
sales NNS I-NP
accounted VBD B-VP
for IN B-PP
47 CD B-NP
% NN I-NP
of IN B-PP
total JJ B-NP
company NN I-NP
sales NNS I-NP
for IN B-PP
the DT B-NP
nine CD I-NP
months NNS I-NP
, , O
compared VBN B-PP
with IN B-PP
50 CD B-NP
% NN I-NP
a DT B-NP
year NN I-NP
earlier RBR B-ADVP
. . O

Sales NNS B-NP
for IN B-PP
the DT B-NP
quarter NN I-NP
rose VBD B-VP
to TO B-PP
$ $ B-NP
1.63 CD I-NP
billion CD I-NP
from IN B-PP
$ $ B-NP
1.47 CD I-NP
billion CD I-NP
. . O

Mevacor NNP B-NP
, , O
Merck NNP B-NP
's POS B-NP
new JJ I-NP
cholesterol-lowering JJ I-NP
drug NN I-NP
, , O
had VBD B-VP
higher JJR B-NP
sales NNS I-NP
than IN B-SBAR
any DT B-NP
other JJ I-NP
prescription NN I-NP
medicine NN I-NP
has VBZ B-VP
ever RB I-VP
achieved VBN I-VP
in IN B-PP
the DT B-NP
U.S. NNP I-NP
in IN B-PP
the DT B-NP
year NN I-NP
following VBG B-PP
introduction NN B-NP
, , O
the DT B-NP
company NN I-NP
said VBD B-VP
. . O

The DT B-NP
drug NN I-NP
was VBD B-VP
introduced VBN I-VP
in IN B-PP
West NNP B-NP
Germany NNP I-NP
this DT B-NP
year NN I-NP
. . O

Intense JJ B-NP
competition NN I-NP
, , O
however RB B-ADVP
, , O
led VBN B-VP
to TO B-PP
unit NN B-NP
sales NNS I-NP
declines NNS I-NP
for IN B-PP
a DT B-NP
group NN I-NP
of IN B-PP
Merck NNP B-NP
's POS B-NP
established VBN I-NP
human NN I-NP
and CC I-NP
animal-health NN I-NP
products NNS I-NP
, , O
including VBG B-PP
Aldomet NNP B-NP
and CC I-NP
Indocin NNP I-NP
. . O

In IN B-PP
New NNP B-NP
York NNP I-NP
Stock NNP I-NP
Exchange NNP I-NP
composite JJ I-NP
trading NN I-NP
yesterday NN B-NP
, , O
Merck NNP B-NP
shares NNS I-NP
closed VBD B-VP
at IN B-PP
$ $ B-NP
75.25 CD I-NP
, , O
up IN B-ADVP
50 CD B-NP
cents NNS I-NP
. . O

Warner-Lambert NNP B-NP
Co NNP I-NP
. . O

Warner-Lambert NNP B-NP
, , O
Morris NNP B-NP
Plains NNP I-NP
, , O
N.J. NNP B-NP
, , O
reported VBD B-VP
sales NNS B-NP
that WDT B-NP
were VBD B-VP
a DT B-NP
record NN I-NP
for IN B-PP
any DT B-NP
quarter NN I-NP
and CC O
the DT B-NP
eighth JJ I-NP
quarter NN I-NP
in IN B-PP
a DT B-NP
row NN I-NP
of IN B-PP
20 CD B-NP
% NN I-NP
or CC I-NP
more RBR I-NP
per-share JJ I-NP
earnings NNS I-NP
growth NN I-NP
. . O

Spurred VBN B-VP
by IN B-PP
growth NN B-NP
in IN B-PP
world-wide JJ B-NP
sales NNS I-NP
of IN B-PP
the DT B-NP
company NN I-NP
's POS B-NP
prescription NN I-NP
drugs NNS I-NP
, , O
Warner-Lambert NNP B-NP
said VBD B-VP
1989 CD B-NP
will MD B-VP
be VB I-VP
the DT B-NP
best JJS I-NP
year NN I-NP
in IN B-PP
its PRP$ B-NP
history NN I-NP
, , O
with IN B-SBAR
per-share JJ B-NP
earnings NNS I-NP
expected VBN B-VP
to TO I-VP
increase VB I-VP
more JJR B-NP
than IN I-NP
20 CD I-NP
% NN I-NP
to TO B-PP
about RB B-NP
$ $ I-NP
6.10 CD I-NP
. . O

Sales NNS B-NP
for IN B-PP
the DT B-NP
quarter NN I-NP
rose VBD B-VP
to TO B-PP
$ $ B-NP
1.11 CD I-NP
billion CD I-NP
from IN B-PP
$ $ B-NP
1.03 CD I-NP
billion CD I-NP
. . O

Prescription-drug NN B-NP
world-wide JJ I-NP
sales NNS I-NP
rose VBD B-VP
9 CD B-NP
% NN I-NP
in IN B-PP
the DT B-NP
quarter NN I-NP
to TO B-PP
$ $ B-NP
340 CD I-NP
million CD I-NP
; : O
U.S. NNP B-NP
sales NNS I-NP
rose VBD B-VP
15 CD B-NP
% NN I-NP
. . O

The DT B-NP
segment NN I-NP
's POS B-NP
growth NN I-NP
was VBD B-VP
led VBN I-VP
by IN B-PP
sales NNS B-NP
of IN B-PP
the DT B-NP
cardiovascular JJ I-NP
drugs NNS I-NP
Lopid NNP B-NP
, , O
a DT B-NP
lipid NN I-NP
regulator NN I-NP
, , O
and CC O
Dilzem NNP B-NP
, , O
a DT B-NP
calcium NN I-NP
channel NN I-NP
blocker NN I-NP
. . O

World-wide JJ B-NP
sales NNS I-NP
of IN B-PP
Warner-Lambert NNP B-NP
's POS B-NP
non-prescription JJ I-NP
health-care NN I-NP
products NNS I-NP
, , O
such JJ B-PP
as IN I-PP
Halls NNP B-NP
cough NN I-NP
tablets NNS I-NP
, , O
Rolaids NNP B-NP
antacid NN I-NP
, , O
and CC O
Lubriderm NNP B-NP
skin NN I-NP
lotion NN I-NP
, , O
increased VBN B-VP
3 CD B-NP
% NN I-NP
to TO B-PP
$ $ B-NP
362 CD I-NP
million CD I-NP
in IN B-PP
the DT B-NP
third JJ I-NP
quarter NN I-NP
; : O
U.S. NNP B-NP
sales NNS I-NP
rose VBD B-VP
5 NN B-NP
% NN I-NP
. . O

Confectionery JJ B-NP
products NNS I-NP
sales NNS I-NP
also RB B-ADVP
had VBD B-VP
strong JJ B-NP
growth NN I-NP
in IN B-PP
the DT B-NP
quarter NN I-NP
. . O

World-wide JJ B-NP
sales NNS I-NP
of IN B-PP
Trident NNP B-NP
gum NN I-NP
, , O
Certs NNP B-NP
breath NN I-NP
mints NNS I-NP
, , O
and CC O
Clorets NNP B-NP
gum NN I-NP
and CC I-NP
breath NN I-NP
mints NNS I-NP
, , O
increased VBN B-VP
12 CD B-NP
% NN I-NP
to TO B-PP
$ $ B-NP
277 CD I-NP
million CD I-NP
. . O

Warner-Lambert NNP B-NP
shares NNS I-NP
closed VBD B-VP
at IN B-PP
$ $ B-NP
109.50 CD I-NP
a DT B-NP
share NN I-NP
, , O
up IN B-ADVP
$ $ B-NP
1.50 CD I-NP
, , O
in IN B-PP
Big NNP B-NP
Board NNP I-NP
composite JJ I-NP
trading NN I-NP
yesterday NN B-NP
. . O

Eli NNP B-NP
Lilly NNP I-NP
& CC I-NP
Co NNP I-NP
. . O

Lilly NNP B-NP
attributed VBD B-VP
record NN B-NP
third-quarter JJ I-NP
and CC I-NP
nine-month JJ I-NP
results NNS I-NP
to TO B-PP
world-wide JJ B-NP
gains NNS I-NP
for IN B-PP
pharmaceuticals NNS B-NP
, , O
medical JJ B-NP
instruments NNS I-NP
and CC O
plant-science NN B-NP
products NNS I-NP
despite IN B-PP
poor JJ B-NP
exchange NN I-NP
rates NNS I-NP
for IN B-PP
the DT B-NP
dollar NN I-NP
that WDT B-NP
slowed VBD B-VP
sales NNS B-NP
abroad RB B-ADVP
. . O

Earnings NNS B-NP
continued VBD B-VP
to TO I-VP
pace VB I-VP
sales NNS B-NP
because IN B-PP
of IN I-PP
a DT B-NP
lower JJR I-NP
tax NN I-NP
rate NN I-NP
, , O
profit NN B-NP
from IN B-PP
the DT B-NP
renegotiation NN I-NP
of IN B-PP
the DT B-NP
debt NN I-NP
instrument NN I-NP
received VBD B-VP
from IN B-PP
Faberge NNP B-NP
Inc. NNP I-NP
in IN B-PP
connection NN B-NP
with IN B-PP
Lilly NNP B-NP
's POS B-NP
sale NN I-NP
of IN B-PP
Elizabeth NNP B-NP
Arden NNP I-NP
Inc. NNP I-NP
in IN B-PP
1987 CD B-NP
, , O
and CC O
net JJ B-NP
proceeds NNS I-NP
from IN B-PP
the DT B-NP
settlement NN I-NP
of IN B-PP
patent NN B-NP
litigation NN I-NP
at IN B-PP
Lilly NNP B-NP
's POS B-NP
Hybritech NNP I-NP
Inc. NNP I-NP
unit NN I-NP
. . O

Third-quarter JJ B-NP
sales NNS I-NP
of IN B-PP
the DT B-NP
Indianapolis NNP I-NP
, , I-NP
Ind. NNP I-NP
, , I-NP
company NN I-NP
rose VBD B-VP
11 CD B-NP
% NN I-NP
to TO B-PP
$ $ B-NP
1.045 CD I-NP
billion CD I-NP
from IN B-PP
$ $ B-NP
940.6 CD I-NP
million CD I-NP
. . O

Nine-month JJ B-NP
sales NNS I-NP
grew VBD B-VP
12 CD B-NP
% NN I-NP
to TO B-PP
$ $ B-NP
3.39 CD I-NP
billion CD I-NP
from IN B-PP
$ $ B-NP
3.03 CD I-NP
billion CD I-NP
a DT B-NP
year NN I-NP
earlier RBR B-ADVP
. . O

Sales NNS B-NP
of IN B-PP
Prozac NNP B-NP
, , O
an DT B-NP
anti-depressant NN I-NP
, , O
led VBN B-VP
drug-sales NNS B-NP
increases NNS I-NP
. . O

Higher JJR B-NP
sales NNS I-NP
of IN B-PP
pesticides NNS B-NP
and CC O
other JJ B-NP
plant-science NN I-NP
products NNS I-NP
more JJR B-VP
than IN I-VP
offset VB I-VP
a DT B-NP
slight JJ I-NP
decline NN I-NP
in IN B-PP
the DT B-NP
sales NNS I-NP
of IN B-PP
animal-health NN B-NP
products NNS I-NP
to TO B-VP
fuel VB I-VP
the DT B-NP
increase NN I-NP
in IN B-PP
world-wide JJ B-NP
agricultural JJ I-NP
product NN I-NP
sales NNS I-NP
, , O
Lilly NNP B-NP
said VBD B-VP
. . O

Advanced NNP B-NP
Cardiovascular NNP I-NP
Systems NNP I-NP
Inc. NNP I-NP
and CC O
Cardiac NNP B-NP
Pacemakers NNPS I-NP
Inc. NNP I-NP
units NNS I-NP
led VBD B-VP
growth NN B-NP
in IN B-PP
the DT B-NP
medical-instrument JJ I-NP
systems NNS I-NP
division NN I-NP
. . O

Lilly NNP B-NP
shares NNS I-NP
closed VBD B-VP
yesterday NN B-NP
in IN B-PP
composite JJ B-NP
trading NN I-NP
on IN B-PP
the DT B-NP
Big NNP I-NP
Board NNP I-NP
at IN B-PP
$ $ B-NP
62.25 CD I-NP
, , O
down RB B-ADVP
12.5 CD B-NP
cents NNS I-NP
. . O

Reuben NNP B-NP
Mark NNP I-NP